LU002
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
- NCT03137771 ↗
- Active, not recruiting
- NRG Oncology
- Deep
We haven't built an HCP commentary report on LU002 (pemetrexed disodium, erlotinib hydrochloride and 3 more in Recurrent Non-Small Cell Lung Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.
The commentary discusses NRG-LU002’s evaluation of local consolidative therapy, including radiation or surgery, alongside maintenance systemic therapy for oligometastatic NSCLC, compared with maintenance therapy alone. Discussion covers the trial population and its heterogeneity, definitions and biology of oligometastatic disease, and how patterns of spread may affect interpretation. Speakers raise questions about whether radiation to local nodes influences immunotherapy response, how the role of local therapy may change as systemic treatments improve, and which patients may be appropriate for treatment. Translational ctDNA analyses are discussed.
Indexed commentary on LU002 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 106 | |
| YouTube | 22 | |
| Podcasts | 10 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer
- Interventions
- 3-Dimensional Conformal Radiation Therapy (3D-CRT); Docetaxel; Gemcitabine; Intensity-Modulated Radiation Therapy (IMRT); Pemetrexed Disodium; Stereotactic Body Radiation Therapy (SBRT); Erlotinib Hydrochloride; Pembrolizumab
- Arms
- Arm 1 (systemic maintenance chemotherapy) · Active comparator
- Arm 2 (LCT + systemic maintenance chemotherapy) · Experimental
- Enrollment
- 218
- Primary outcomes
- [Phase II] Progression-free Survival
- [Phase III] Overall Survival
- Sponsor
- NRG Oncology with National Cancer Institute (NCI)
- Start
- Apr 7, 2017
- Primary completion
- Dec 20, 2023
- Results posted
- Yes
- Registry record
- NCT03137771 · updated Jun 8, 2026
Publications
linked from the registry- Mattes MD, Eubank TD, Almubarak M, Wen S, Marano GD, Jacobson GM, Ma PC. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer. Clin Lung Cancer. 2021 Jul;22(4):268-273. doi: 10.1016/j.cllc.2021.01.012. Epub 2021 Jan 25. PubMed 33608212